Barclays PLC Procept Bio Robotics Corp Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Procept Bio Robotics Corp stock. As of the latest transaction made, Barclays PLC holds 77,934 shares of PRCT stock, worth $7.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

77,934

Previous 77,934 -0.0%

Holding current value

$7.29 Million

Previous $6.24 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$56.31 - $84.99 $3.52 Million - $5.32 Million	62,599 Added 408.21%	77,934 $6.24 Million
Q2 2024 Aug 14, 2024	SELL	$45.73 - $69.19 $1.02 Million - $1.54 Million	-22,241 Reduced 59.19%	15,335 $937,000
Q1 2024 May 15, 2024	SELL	$40.38 - $50.75 $1.08 Million - $1.36 Million	-26,813 Reduced 41.64%	37,576 $1.86 Million
Q4 2023 Feb 15, 2024	BUY	$24.89 - $43.41 $317,994 - $554,606	12,776 Added 24.75%	64,389 $2.7 Million
Q3 2023 Nov 07, 2023	BUY	$30.02 - $38.81 $1.07 Million - $1.39 Million	35,746 Added 225.29%	51,613 $1.69 Million
Q2 2023 Aug 03, 2023	BUY	$26.7 - $37.02 $70,995 - $98,436	2,659 Added 20.13%	15,867 $561,000
Q1 2023 May 04, 2023	BUY	$26.64 - $39.74 $166,446 - $248,295	6,248 Added 89.77%	13,208 $375,000
Q4 2022 Feb 13, 2023	BUY	$38.78 - $46.78 $227,832 - $274,832	5,875 Added 541.47%	6,960 $290,000
Q3 2022 Nov 03, 2022	SELL	$30.9 - $50.65 $6,180 - $10,130	-200 Reduced 15.56%	1,085 $45,000
Q2 2022 Aug 12, 2022	BUY	$29.23 - $44.45 $3,215 - $4,889	110 Added 9.36%	1,285 $42,000
Q1 2022 May 16, 2022	BUY	$16.89 - $35.74 $19,845 - $41,994	1,175 New	1,175 $41,000

Others Institutions Holding PRCT

# of Institutions

266

Shares Held

38M

Call Options Held

262K

Put Options Held

257K

View Full List

About PROCEPT BioRobotics Corp

Ticker PRCT
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 44,592,300
Market Cap $4.17B
Description
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aqu...

More about PRCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account